Neurogene’s (NGNE) “Outperform” Rating Reaffirmed at William Blair

Neurogene (NASDAQ:NGNE)‘s stock had its “outperform” rating reiterated by William Blair in a research note issued to investors on Tuesday,RTT News reports.

Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets dropped their target price on shares of Neurogene from $65.00 to $60.00 and set an “outperform” rating on the stock in a report on Tuesday, November 12th. Stifel Nicolaus raised their price objective on Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Neurogene in a report on Tuesday. Robert W. Baird increased their price target on Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, November 12th. Finally, Leerink Partners lifted their price objective on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Neurogene has a consensus rating of “Buy” and an average target price of $63.33.

Neurogene Trading Down 6.8 %

Shares of Neurogene stock traded down $1.34 on Tuesday, reaching $18.48. 344,797 shares of the company were exchanged, compared to its average volume of 150,370. Neurogene has a one year low of $12.49 and a one year high of $74.49. The company has a 50-day moving average of $46.80 and a 200 day moving average of $40.09.

Institutional Trading of Neurogene

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of Neurogene in the first quarter valued at approximately $120,000. Vanguard Group Inc. raised its holdings in Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after acquiring an additional 457,062 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in Neurogene by 0.6% in the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after acquiring an additional 2,499 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Neurogene during the 2nd quarter valued at $1,107,000. Finally, Rhumbline Advisers acquired a new stake in shares of Neurogene during the 2nd quarter worth $491,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.